How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism?

European Journal of Endocrinology

Volumn 167, Issue 3, 2012, Pages 295-299

  Biondi, Bernadette ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THYROTROPIN; THYROXINE;

ADJUVANT THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; DRUG MEGADOSE; HEART ATRIUM FIBRILLATION; HORMONE DETERMINATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); NOTE; OVERT HYPERTHYROIDISM; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; SUBCLINICAL HYPERTHYROIDISM; THROMBOEMBOLISM; THYROTROPIN BLOOD LEVEL;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTHYROIDISM; META-ANALYSIS AS TOPIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84865769600     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0585     Document Type: Note

References (36)

1. Parry CH. Enlargement of the thyroid gland in connection with enlargement or palpitation of the heart. Collections from the unpublished papers of the late Caleb Hillier Parry 111-125, 1825.
2. Graves RJ. Newly observed affections of the thyroid gland in females. London Medical and Surgical Journal 1835 7 516-517.
3. Völzke H, Schwahn C, Wallaschofski H & Dörr M. Review: the association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? Journal of Clinical Endocrinology and Metabolism 2007 92 2421-2429. (doi:10.1210/jc.2007-0179)
4. Brandt F, Green A, Hegedüs L & Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. European Journal of Endocrinology 2011 165 491-497. (doi:10.1530/EJE-11-0299)
5. Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP & Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a metaanalysis. International Journal of Cardiology 2008 28 41-48. (doi:10.1016/j.ijcard.2007.02.027)
6. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J & Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Annals of Internal Medicine 2008 148 832-845.
7. Haentjens P, Van Meerhaeghe A, Poppe K & Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. European Journal of Endocrinology 2008 159 329-341. (doi:10.1530/EJE-08-0110)
8. Yang LB, Jiang DQ, Qi WB, Zhang T, Feng YL, Gao L & Zhao J. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. European Journal of Endocrinology 2012 167 75-84. (doi:10.1530/EJE-12-0015)
9. Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Asvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP & Rodondi N, for the Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archives of Internal Medicine 2012 172 799-809.
10. Goldman MB, Monson RR & Maloof F. Cancer mortality in women with thyroid disease. Cancer Research 1990 50 2283-2289.
11. Parle JV, Maisonneuve P, Sheppard MC, Boyle P & Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001 358 861-865. (doi:10.1016/S0140-6736(01)06067-6)
12. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M & Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. Journal of the American Medical Association 2004 292 2591-2599. (doi:10.1001/jama.292.21.2591)
13. Osman F, Franklyn J, Holder rL, Sheppard MC & Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. Journal of the American College of Cardiology 2007 49 71-81. (doi:10.1016/j.jacc.2006.08.042)
14. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H & Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2007 92 2190-2196. (doi:10.1210/jc.2006-2321)
15. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J & Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. New England Journal of Medicine 1998 338 712-718. (doi:10.1056/NEJM199803123381103)
16. Biondi B & Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nature Reviews. Endocrinology 2010 6 431-443. (doi:10.1038/nrendo.2010.105)
17. Biondi B. Cardiovascular mortality in subclinical hyperthyroidism: an ongoing dilemma. European Journal of Endocrinology 2010 162 587-589. (doi:10.1530/EJE-09-1095)
18. Flynn RW, Macdonald TM, Jung RT, Morris AD & Leese GP. Mortality and vascular outcomes in patients treated for thyroid dysfunction. Journal of Clinical Endocrinology and Metabolism 2006 91 2159-2164. (doi:10.1210/jc.2005- 1833)
19. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP & Ladenson PW. Thyroid status, cardiovascular risk, and mortality in older adults. Journal of the American Medical Association 2006 295 1033-1041. (doi:10.1001/jama.295.9.1033)
20. Nanchen D, Gussekloo J, Westendorp RG, Stott DJ, Jukema JW, Trompet S, Ford I, Welsh P, Sattar N, Macfarlane PW, Mooijaart SP, Rodondi N & de Craen AJ, PROSPER. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2012 97 852-861. (doi:10.1210/jc.2011-1978)
21. Squizzato A, Gerdes VEA, Brandjes DPM, Büller HR & Stam J. Thyroid diseases and cerebrovascular disease. Stroke 2005 36 2302-2310. (doi:10.1161/01.STR.0000181772.78492.07)
22. Lin HC, Yang LY & Kang JH. Increased risk of pulmonary embolism among patients with hyperthyroidism: a 5-year follow-up study. Journal of Thrombosis and Haemostasis 2010 8 2176-2181. (doi:10.1111/j.1538-7836.2010.03993.x)
23. Nakazawa HK, Sakurai K, Hamada N, Momotani N & Ito K. Management of atrial fibrillation in the post-thyrotoxic state. American Journal of Medicine 1982 72 903-906. (doi:10.1016/0002-9343(82)90850-6)
24. Hall P, Lundell G & Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinologica 1993 128 230-234.
25. Nyirenda MJ, Clark DN, Finlayson AR, Read J, Elders A, Bain M, Fox KA & Toft AD. Thyroid disease and increased cardiovascular risk. Thyroid 2005 15 718-724. (doi:10.1089/thy.2005.15.718)
26. McDermott MT, Kidd GS, Dodson LE Jr & Hofeldt FD. Radioiodine-induced thyroid storm. Case report and literature review. American Journal of Medicine 1983 75 353-359. (doi:10.1016/0002-9343(83)91217-2)
27. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN & American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011 21 593-646. (doi:10.1089/thy.2010.0417)
28. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Muller-Brand J & Muller B. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007 334 7592-7598. (doi:10.1136/bmj.39114.670150.BE)
29. Franklyn JA, Sheppard MC & Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. Journal of the American Medical Association 2005 294 71-80. (doi:10.1001/jama.294.1.71)
30. Biondi B. Should we treat all subjects with subclinical thyroid disease the same way? European Journal of Endocrinology 2008 159 343-345. (doi:10.1530/EJE-08-0527)
31. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Saccà L, Filetti S, Lombardi G & Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. Journal of Clinical Endocrinology and Metabolism 2000 85 4701-4705. (doi:10.1210/jc.85.12.4701)
32. Biondi B & Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008 29 76-131. (doi:10.1210/er.2006- 0043)
33. Biondi B & Cooper DS. Subclinical thyroid disease. Lancet 2012 379 1142-1154. (doi:10.1016/S0140-6736(11)60276-6)
34. Faber J, Wiinberg N, Schifter S & Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. European Journal of Endocrinology 2001 145 391-396. (doi:10.1530/eje.0.1450391)
35. Sgarbi JA, Villaça FG, Garbeline B, Villar HE & Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. Journal of Clinical Endocrinology and Metabolism 2003 88 1672-1677. (doi:10.1210/jc.2002-021046)
36. Kaminski G, Michalkiewicz D, Makowski K, Podgajny Z, Szalus N, Ruchala M, Szczepanek E & Gielerak G. Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism. Clinical Endocrinology 2011 74 501-507. (doi:10.1111/j.1365-2265. 2010.03957.x)